Search Results for: anti-aging

Weekly reads: Vertex, stem cells for MS, Athersys, 900-day paper review at Nature

/ / 1 Comment
“While still early, these results support the continued progression of our VX-880 clinical studies, as well as future studies using our encapsulated islet cells, which hold the potential to be used without the need for immunosuppression,” said Bastiano Sanna, Ph.D., executive vice president and chief of cell and genetic therapies at Vertex.

Vertex Pharmaceuticals has a lot going for it right now on the cell therapy front. For instance, they have the strongest type 1 diabetes cell therapy pipeline after some recent acquisitions. Still it’s not a simple matter to succeed in the cell therapy space even with one therapy for one targeted disease. Trials are tough […]

Weekly reads: Vertex, stem cells for MS, Athersys, 900-day paper review at Nature Read More »

Weekly reads: Xist & autoimmune disease in women, Crohn’s disease, dumb headline of the week

/ / Leave a Comment
Xist ,auto immune disease

Readers of The Niche have asked me many questions about stem cells for autoimmune disease but the puzzle of why women get these conditions more often than men hasn’t come up before here. For instance, why is MS so much more common in women than men? It’s remained somewhat of a mystery over the years.

Weekly reads: Xist & autoimmune disease in women, Crohn’s disease, dumb headline of the week Read More »

Textbook case of bad media on ‘stem cell treatment’ clinic: Kirk Cousins Caribbean trip

/ / 9 Comments
Kirk Cousins, stem cell treatment

It’s frustrating to see so much bad media coverage of celebrity trips to clinics to get supposed stem cell treatment of various kinds. Part of the concern here stems from ordinary people taking risks by following the example of the famous people.  Good journalism should ask tough questions, talk to experts, and not yield an

Textbook case of bad media on ‘stem cell treatment’ clinic: Kirk Cousins Caribbean trip Read More »

Weekly reads: MiMedX & Kimera Labs FDA warnings, NYT on Bryan Johnson, MUSE cell trial

/ / 10 Comments
AXIOFILL, MiMedx

Placental biologics firm MiMedx and exosome company Kimera Labs both recently received FDA warning letters. The letter to MiMedx was related to its placental biologics products and procedures. The new warning to Kimera Labs was about its exosome products and an amniotic product. Let’s compare these letters starting with the one to MiMedX. MiMedx warning letter

Weekly reads: MiMedX & Kimera Labs FDA warnings, NYT on Bryan Johnson, MUSE cell trial Read More »

Fountain Life update: lawsuit by doc, high performance aging, Celularity trial plan

/ / Leave a Comment
Fountain Life

A New Rochelle doctor has filed suit against the healthcare clinic firm Fountain Life alleging fraud. Now seems like a good time for an update on the firm. Peter Diamandis along with Bob Hariri, life coach Tony Robbins, and surgeon William Kapp founded Fountain Life, an early detection-focused healthcare company. Are they also a longevity firm? To

Fountain Life update: lawsuit by doc, high performance aging, Celularity trial plan Read More »

20 stem cell & regenerative medicine predictions for 2024

/ / 4 Comments
Stem cell, crystal ball, predictions

Each year I make predictions for the stem cell and regenerative medicine field for the following year. Today’s prediction post is focused on what to expect in 2024. You can also see my stem cell predictions for 2023 and my grades on how I did. I also have made a video version of these predictions so please

20 stem cell & regenerative medicine predictions for 2024 Read More »

Weekly reads: RMAT jump, tissues as liquid crystals, gov stem cell advisor scammed of $650K

/ / Leave a Comment
RMAT, FDA data

The FDA has a unique mechanism called RMAT or regenerative medicine advanced therapy designation. It’s intended to move investigational regenerative therapies forward more effectively. RMAT data I recently updated The Niche RMAT list and it has jumped to 85. The FDA has approved many new RMATs this year. The data on how many applications the FDA

Weekly reads: RMAT jump, tissues as liquid crystals, gov stem cell advisor scammed of $650K Read More »

Weekly reads: FDA OKs 2 gene therapies for sickle cell, new Paolo Macchiarini series, Fujifilm

/ / 1 Comment
Marie Tornyenu, Casgevy gene therapies for sickle cell

The big news broke Friday that the FDA approved two new gene therapies for sickle cell disease. While the approvals were expected and the actual use of these treatments will be complex on several levels, this is a historic development. 2 FDA-approved gene therapies for sickle cell Friday’s news follows on recent UK approval for

Weekly reads: FDA OKs 2 gene therapies for sickle cell, new Paolo Macchiarini series, Fujifilm Read More »

Can trying to cheat death paradoxically kill you sooner?

/ / 10 Comments
anti-aging, Dorian Gray

Can you paradoxically kill yourself early by trying to cheat Death? For example, die through risky anti-aging approaches? The question came to mind because such longevity efforts have become more extreme. They also get more hype in the media. I’ve been following the anti-aging space mainly because many interventions involve risky stem cell injections. Those

Can trying to cheat death paradoxically kill you sooner? Read More »

Weekly reads: stem cells for MS, good news x2, extending dog years, Neuralink updates

/ / 2 Comments
stem cells for MS

For about as long as I’ve been writing The Niche, people have been asking about stem cells for MS. There’s a huge need for new therapies. While a chemo-based approach with autologous hematopoietic stem cell transplantation (HSCT) looks to work for certain cases of multiple sclerosis (although not yet approved in the US), other cell

Weekly reads: stem cells for MS, good news x2, extending dog years, Neuralink updates Read More »